Development of a Serocorrelate of Protection Against Invasive Group B Streptococcus Disease

Launched by ST GEORGE'S, UNIVERSITY OF LONDON · Jan 28, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a potential vaccine to protect infants from a serious infection caused by a bacteria called Group B Streptococcus (GBS). The researchers want to understand if measuring a specific immune marker in the blood (called anti-GBS IgG concentration) can help predict which babies are at risk of developing invasive GBS disease. By finding a strong link between this immune marker and the disease, the goal is to show that a vaccine could effectively reduce the chances of infants getting sick from GBS.

To participate in this study, infants under 90 days old are eligible, but parents or guardians must give their permission for them to join. If a baby has already been diagnosed with GBS disease, their parent must also agree to allow them to be part of the study. Participants can expect to undergo tests to measure the immune marker and may receive the potential vaccine being tested. This trial is currently recruiting participants and aims to gather important information that could lead to better protection for infants against this infection.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • -
• Exclusion Criteria:
• • For iGBS disease case recruitment, an infant is not eligible unless a parent/person with parental responsibility gives informed consent For iGBS disease control recruitment, a mother is not eligible unless she gives informed consent.